Crossject Appoints Tony Tipton as U.S. Chief Operating Officer to Prepare for ZEPIZURE Epilepsy Rescue Treatment Launch
Press Release
Crossject Appoints Tony Tipton as U.S. Chief Operating Officer to Prepare for ZEPIZURE Epilepsy Rescue Treatment Launch
An experienced executive has been chosen to spearhead efforts for the U.S. launch of ZEPIZURE.
This strategic appointment strengthens and mitigates risks associated with pre-commercial activities as the company prepares to submit its marketing authorization application for the ZEPIZURE epilepsy rescue treatment in the U.S.
Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical firm focused on developing emergency medicines through its award-winning needle-free auto-injector ZENEO®, has announced the appointment of Tony Tipton as the U.S. Chief Operating Officer.
Mr. Tipton brings more than 25 years of experience in critical areas of the commercial pharmaceuticals sector, including corporate leadership, business development, market access, sales management, and marketing operations. Previously, he served as the Chief Operating & Commercial Officer at Xequel Bio, where he crafted and executed a commercialization strategy and managed pre-commercial initiatives for BARDA/NIH funded projects, in addition to overseeing commercial assets acquired by the company. His expertise is expected to enhance Crossject’s pre-commercial efforts in the U.S. as the company prepares to submit its marketing authorization application for ZEPIZURE.
Before joining Crossject, Mr. Tipton held several key commercial positions in leading international specialty pharmaceutical companies. Notably, he was the Interim Chief Commercial Officer and Vice President of Market Access & Trade Channels at Santen Pharmaceuticals, following its acquisition of Eyevance Pharmaceuticals. In this role, he effectively led U.S. commercial operations, achieving over $70 million in gross revenue. His extensive experience also includes a Director’s role for Health Systems Accounts at Sunovion Pharmaceuticals, where he successfully launched the epilepsy medication Aptiom, along with various sales and marketing positions at Galderma Laboratories.
“Tony brings a proven track record of excellence and highly relevant experience across all aspects of pre-commercial, sales, and marketing in the specialty pharmaceutical industry, particularly for emergency medicines similar to ZEPIZURE. His leadership and expertise are ideally suited to guide us toward our commercialization goals in the U.S., which is our primary market. We eagerly anticipate the dynamic contributions he will make to our team,” stated Patrick Alexandre, CEO of Crossject.
“My senior leadership roles in preparing companies for commercialization have equipped me with valuable experience and networks. I am excited to join Crossject at this critical juncture as we work to bring lifesaving rescue medicines like ZEPIZURE to market. The ZENEO technology platform and Crossject’s promising pipeline offer numerous opportunities for expansion. I look forward to applying my commercial strategy experience and collaborating with the talented team at Crossject as we aim to launch the company’s first rescue therapy,” remarked Tony Tipton, COO of Crossject U.S.
About Crossject
Crossject SA (Euronext: ALCJ) is an emerging specialty pharmaceutical company dedicated to developing medicines for emergency situations using its award-winning needle-free auto-injector ZENEO® platform. The company is advancing regulatory development for ZEPIZURE, an epilepsy rescue therapy, supported by a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The versatile ZENEO® platform enables patients or untrained caregivers to quickly and easily administer various emergency medications intramuscularly, even through clothing. Crossject is also working on additional products aimed at treating allergic reactions, adrenal insufficiency, and other emergency conditions.
Contact Information
Investors
Natasha Drapeau
Cohesion Bureau
+41 76 823 75 27
natasha.drapeau@cohesionbureau.com
Media
Sophie Baumont
Cohesion Bureau
+33 6 27 74 74 49
sophie.baumont@cohesionbureau.com
Frequently Asked Questions
1. Who has been appointed as the U.S. Chief Operating Officer for Crossject?
Tony Tipton has been appointed as the U.S. Chief Operating Officer for Crossject.
2. What is ZEPIZURE?
ZEPIZURE is an epilepsy rescue treatment developed by Crossject, utilizing their advanced needle-free auto-injector technology.
3. What experience does Tony Tipton bring to Crossject?
Tony Tipton has over 25 years of experience in the pharmaceutical industry, specifically in areas such as corporate leadership, business development, and market access.
4. How does Crossject's ZENEO® platform work?
The ZENEO® platform allows emergency medications to be administered intramuscularly by patients or caregivers easily and rapidly, even through clothing.
5. What other therapeutic areas is Crossject exploring?
Crossject is also developing treatments for allergic shocks, adrenal insufficiencies, and other emergency indications.
